Antibody response in six HACEK endocarditis cases under therapy

Area of Science:

• Infectious Diseases
• Immunology
• Microbiology

Background:

• HACEK (Haemophilus spp., Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae) group bacteria are a significant cause of infective endocarditis.
• Accurate diagnosis and monitoring of HACEK endocarditis are crucial for effective patient management.

Observation:

• Antibody responses were measured in six patients with HACEK endocarditis using complement fixation assays with patient sera and crude bacterial antigens.
• Titers were correlated with clinical status and C-reactive protein (CRP) levels.
• Five out of six patients demonstrated measurable antibody responses that could be monitored during therapy.

Findings:

• Antibody titers against causative HACEK isolates were successfully monitored in five patients, showing changes that correlated with treatment response and clinical improvement.
• In one case of Actinobacillus actinomycetemcomitans endocarditis, immediate therapy prevented significant antibody titer development.
• C-reactive protein levels also correlated with disease activity and treatment response.

Implications:

• The complement fixation assay is a practical method for monitoring antibody responses in HACEK endocarditis patients undergoing therapy.
• Further research is needed to establish the utility of this assay for diagnosing culture-negative HACEK endocarditis.
• This assay can aid in assessing treatment efficacy and patient recovery in HACEK endocarditis.